Wire · operational-macro
FDA Grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
The FDA has granted Fast Track designation to QRX003 for treating peeling skin syndrome (PSS), a rare genetic skin disorder with no current approved treatment. Quoin Pharmaceuticals plans a phase 2/3 clinical trial enrolling up to 12 patients, targeting a 2028 approval.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You face a unique chance to enter peeling skin syndrome treatment now that QRX003 has fast track status and a rare pediatric designation with FDA. This creates expedited regulatory paths and opens clinical proof points for related rare skin disorders ahead of potential approval.
◆ Coverage
1 source · 22 Sep 2026
◆ Related on Wire
◆ Topics